The next
generation...

Robin Cohen

Chief Executive Officer & Executive Director

Robin has over 25 years of experience in the pharmaceutical industry with a strong commercial and business development focus.  Robin has worked in both commercial and Business Development roles at Janssen Cilag (Johnson & Johnson) as well as executive level positions in the biotech space.  Prior to joining aVaxziPen, Robin worked as Chief Business Officer at Emergex Vaccines.  Robin leads all aspects of commercial development and partnering for the organisation.

Dr Carolyn Mercer

Financial Controller

Carolyn joined aVaxziPen in August 2023.  Carolyn was originally a research scientist, gaining her PhD in Molecular Virology in 2007 from Oxford Brookes University, before qualifying as a chartered accountant with CIMA in 2013.

Prior to joining aVaxziPen, Carolyn was Senior Business Partner at Williams Racing.  Her role included collaborating with senior leadership and the engineering teams to maximise car performance in the cost cap era of Formula One.

Prior to this Carolyn held roles in Commercial and Corporate Finance across various companies including Baxter Healthcare, Vodafone Business and Macmillan Publishers.

Dr Keith Howard

Chief Scientific Officer

Keith brings more than 35 years of experience in vaccine development spent in industry and academia and has led the development of viral vectors and vaccines across multiple formats (recombinant, viral vector, live attenuated virus) at several biotechnology and pharmaceutical companies.

Prior to joining aVaxziPen, Keith was Chief Development Officer at Oxford-based Vaccitech, where he was the head of R&D, process development and manufacturing for its novel viral vector vaccine programmes. Before that, he was Senior Director and Head of Manufacturing Science & Technology for FluMist (live attenuated influenza vaccine) at Medimmune.

Before this, Keith was a Director of Vaccines Analytical Development at Pfizer Biotech, and he also spent ten years at Baxter AG in various positions including that of Director of Vaccines R&D. Further roles included Head of Vector Development at Oxxon Therapeutics and Director of Neuronal Gene Therapy at Cantab Pharmaceuticals.

Keith spent 13 years in academia studying infectious diseases, virology and immunology at University College London and the London School of Hygiene and Tropical Medicine. He received a BSc in Biological Sciences from the University of Leicester and a PhD in Molecular Parasitology from the University of London.

Karen Stoddart

Chief Operating Officer & Executive Director

Karen has extensive experience in the pharmaceutical industry gained in the development, manufacture and regulatory assurance of vaccines, biologics, active pharmaceutical ingredients and medicinal drug products.

She has worked in Europe and USA as well as UK and has led projects to prepare companies for their first global new drug registration and associated inspections from the regulatory authorities, including MHRA, EMA, FDA and ANVISA.

Prior to furthering her career in Regulatory and Quality, Karen worked in R & D and Operations. She has supported the conduct of safety and clinical efficacy studies around the world and has championed the introduction of new and improved quality systems to support Good Clinical, Manufacturing, Laboratory and Distribution Practices. As a member of the core team, she has been involved in new build, construction and remediation of pharmaceutical facilities for active ingredients, sterile and high risk medicinal products and has led the associated qualification and validation effort.

Karen’s experience has been gained in GSK, MSD, Chiroscience, Celltech, NextPharma Technologies, GW Pharmaceuticals, Sandoz and Vaccine Manufacturing and Innovation Centre. She is the Chair of Research Ethics at Cranfield University and is a Public Partner for National institute for Health and Care Research in conjunction with Imperial College, London.

Christopher Macgregor

Head of Research & Development

Chris has worked in novel pharmaceutical delivery technology development for more than 12 years and has a strong background in process development and pharmaceutical engineering.

Prior to his appointment as Head of Research and Development at aVaxziPen Chris worked as a Manufacturing Engineer and subsequently Head of Manufacturing.  He has led the development of manufacturing processes from laboratory bench to GMP-scale operation. In 2016 he oversaw a successful phase I clinical trial.

In his current role Chris manages the R&D team within aVaxziPen and supports technical, Business Development and strategic activities within the company.

Chris holds a BA and MEng in Engineering from the University of Cambridge (UK).

Carol Lloyd

Executive Assistant & Company Secretary

Carol has over 20 years’ Biotech and Life Sciences experience working alongside C-Suite Executives and more than 10 years in a Company Secretary role.

Prior to joining aVaxziPen, Carol supported senior leadership at Oxford Diffraction, to sell Diffraction systems to Universities and Commercial Clients.  She was an integral part of the Team that implemented a successful sale of the Company, in 2008, to Varian Inc and later Agilent Technologies.

Carol worked as the Harwell Centre Business Manager at Synexus, a phase II-IV clinical trials patient recruitment company spun out of AEA Technology and the Edgebright Partnership.  She was responsible for building relationships with General Practitioners, Pharmaceutical Companies, Clinical Research Organisation, Hospital Consultants and Ethics Committees to successfully identify patients for clinical trials in women’s healthcare, osteoporosis, arthritis, IBS and migraine.  She also led a team of Medical Practitioners, Nurses, Radiographers and Administrators who implemented the clinical studies.

Carol holds a Professional Certificate in Management from the Open University, UK.

Professor Jayne Hope

Professor Jayne Hope obtained a degree in Biological Sciences from the University of Birmingham, UK in 1991, and a PhD degree from the University of Manchester, UK in 1994. She then carried out postdoctoral research at Kings College, London, UK and subsequently at the Institute for Animal Health, Compton, UK.

Professor Hope joined The Roslin Institute, University of Edinburgh, UK in 2011 and was awarded a personal chair in immunology in 2017. Her research group studies cellular immune responses in cattle with a particular focus on understanding the role of innate cells in driving natural and vaccine-induced immunity to mycobacterial diseases including bovine tuberculosis and Johne’s disease. She also leads the Immunological Toolbox at The Roslin Institute.

Professor James Birchall

James is Professor of Pharmaceutical Sciences and Deputy Head of the School of Pharmacy and Pharmaceutical Sciences, Cardiff University. Professor Birchall graduated from Bath University in 1993 and completed his PhD researching drug and DNA delivery systems in 1998 (Cardiff University). Current research includes microneedle delivery of contraceptives, therapeutics, immunotherapeutics and vaccines into the skin and pulmonary drug delivery.

James has acted as Associate Editor of Critical Reviews in Therapeutic Drug Carrier Systems, a member of the Editorial Board of Expert Review of Medical Devices, a temporary advisor to the WHO and an expert advisor to the British Pharmacopoeia and conducted research funded by the EU, PATH, Bill & Melinda Gates Foundation, NIH, Wellcome Trust, EPSRC, MRC, Welsh Government, Royal Society, Innovate UK and various charities and pharmaceutical companies.

Campbell Bunce PhD

Campbell is Chief Scientific Officer (CSO) and Cambridge Site Head at Abzena and has a PhD in Immunology from the University of Manchester, an Executive MBA from Judge Business School, Cambridge University and has published a number of papers on cell-mediated immunity, immunotherapy and vaccines.

Campbell has over 25 years of experience working in the biotech and diagnostics sector. Throughout his career he has applied innovative solutions for the design, manufacture and clinical evaluation of novel products including vaccines, biologics, and small molecules in multiple therapeutic areas. These include inflammation, cancer, infectious disease, and addiction.